Fully home-based methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face or scalp: A real life open study

García-Gil, Miguel Fernando (Universidad de Zaragoza) ; Gracia-Cazaña, Tamara (Universidad de Zaragoza) ; Cerro-Muñoz, Paulina ; Bernal-Masferrer, Laura ; Navarro-Bielsa, Alba (Universidad de Zaragoza) ; Gilaberte, Yolanda (Universidad de Zaragoza)

Resumen: Methyl aminolevulinate daylight photodynamic therapy (MAL DL-PDT) is highly effi-cacious for the treatment of nonhyperkeratotic actinic keratosis (AK), even when par-tially performed at home. To evaluate the long-term effectiveness, safety, andpatient-reported outcomes of MAL DL-PDT performed completely by the patient inreal life conditions. An open prospective study was conducted in Spain amongpatients diagnosed with at least five AK lesions on the face or the scalp. Patientsreceived instruction and information in infographic format to perform MAL DL-PDTat home. All had been treated with 30% urea daily for 7 days before the day of MALDL-PDT. Meteorological conditions on the day of the treatment and adverse effectswere recorded. Patients underwent follow-up, and a second session of home-basedMAL DL-PDT if deemed necessary, 3, 6, and 12 months after the initial treatmentsession. The study population consisted of 22 patients (19 men and three women,mean [standard deviation, SD] age, 72.05 [6.96] years). A complete response wasobserved in 47.7% of AK lesions at 3 months (p< 0.001) and 65.9% (n=199) at12 months (p< 0.001). Olsen grade II lesions showed the highest rate of response(76.07% at 12 months). The mean (SD) actinic keratosis area and severity index scoredecreased significantly from 4.99 (2.43) at baseline to 2.33 (1.01) at 12 months(p=0.0234). Adverse effects were mild and expected. A majority of patients were“satisfied”or“very satisfied”with the treatment instruction provided (90.9%) andthe treatment outcome (72.7%). MAL DL-PDT can be applied at home like any othertopical treatment for AK. Our results indicate good long-term effectiveness, a highlevel of patient satisfaction, and no significant side effects

Idioma: Inglés

DOI: 10.1111/dth.15879

Año: 2022

Publicado en: Dermatologic Therapy 35, 11 (2022), e15879 [4 pp.]
ISSN: 1396-0296

Factor impacto JCR: 3.6 (2022)

Categ. JCR: DERMATOLOGY rank: 16 / 70 = 0.229 (2022) - Q1 - T1

Factor impacto CITESCORE: 4.7 - Medicine (Q2)

Factor impacto SCIMAGO: 0.667 - Dermatology (Q1) - Medicine (miscellaneous) (Q2)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Dermatología (Dpto. Medicina, Psiqu. y Derm.)